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Background: Quality of life (QoL) is increasingly recognized as central to the broad construct of recovery in
patients with substance use disorders (SUD). However, few longitudinal studies have evaluated changes in QoL
after SUD treatment and included patients with SUD that were compulsorily hospitalized. This study aimed to
describe QoL among in-patients admitted either voluntarily or compulsorily to hospitalization and to examine
patterns and predictors of QoL at admission and at 6 months post treatment.
Methods: This prospective study followed 202 hospitalized patients with SUD that were admitted voluntarily
(N=137) or compulsorily (N=65). A generic QoL questionnaire (QoL-5) was used to assess QoL domains.
Regression analysis was conducted to identify associations with QoL at baseline and to examine predictors of
change in QoL at a 6-month follow-up.
Results: The majority of patients had seriously impaired QoL. Low QoL at baseline was associated with a high
psychiatric symptom burden. Fifty-eight percent of patients experienced a positive QoL change at follow-up. Although
the improvement in QoL was significant, it was considered modest (a mean 0.06 improvement in QoL-5 scores at
follow-up; 95% confidence interval: 0.03 - 0.09; p<0.001). Patients admitted voluntarily and compulsorily showed QoL
improvements of similar magnitude. Female gender was associated with a large, clinically relevant improvement in
QoL at follow-up.
Conclusions: In-patient SUD treatment improved QoL at six month follow-up. These findings showed that QoL
measurements were useful for providing evidence of therapeutic benefit in the SUD field.
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The concept of quality of life (QoL) is used in medicine
for measuring a patient’s subjective view of overall well-
being. It serves as a complementary perspective to a
traditional disease-specific perspective. The most prom-
ising use of the QoL concept is as an outcome measure
in clinical trials [1] and health services research [2]. This
broad evaluation is particularly useful in the context of
chronic disorders, where it is often possible to improve
patient living conditions, though a complete absence of
symptoms may be out of reach [3]. With the recognition
that measures of disease status alone are insufficient to
describe the burden of illness in chronic and severe* Correspondence: adrian.razvan.pasareanu@sshf.no
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unless otherwise stated.disorders, clinical research has rapidly employed QoL as
an integral outcome variable [4].
Substance use disorder (SUD) is often considered a
chronic, relapsing disease that is typically associated with
psychiatric, somatic, and social comorbidities, in addition
to a shortened life expectancy [5]. Traditionally, addiction
treatment has focused on abstinence from substances;
however, this “narrow” aim for treatment efficiency has re-
cently been criticized. Increasingly, the addiction field is
recognizing the importance of focusing on other positive
treatment outcomes and recovery [6,7]. Recovery has been
generally considered a period of time characterized by an
enduring reduction in substance use, improved personal
health, and improved social function. Thus, QoL is also
relevant to SUD, because it is a construct that incorpo-
rates the individual’s subjective view of a range of clinical,
functional, and personal variables [8].tral. This is an Open Access article distributed under the terms of the Creative
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are currently available to stabilize patients and reduce
harm, thereby increasing life expectancy and QoL [9].
Chronic illnesses have been treated for indeterminate
periods, and treatment effects are typically evaluated
during the course of those treatments [7]. Monitoring
the outcome with specific measures of recovery can
produce more efficient, clinically relevant, accountable
evaluations. Applying this methodology to the SUD
field has given rise to expectations of similar accuracy
in evaluating outcomes. Moreover, it has been sug-
gested that these outcomes should be collected and re-
ported immediately and regularly by clinicians from
the beginning of addiction treatment sessions, to sup-
port evaluations of recovery progress and decision-
making with regard to continuing care [7]. Currently,
there is evidence that QoL will improve as a function
of treatment and recovery in patients with SUD [10-12].
Emerging changes in the SUD treatment field will require
the incorporation of QoL indices in treatment develop-
ment and research [13].
Despite relatively little research that focuses on QoL
among the SUD population, it has been shown that QoL
is consistently low among individuals with SUD that ac-
tively seek treatment compared to individuals without
SUD or those with chronic psychiatric conditions [14].
However, few longitudinal studies exist; thus, it remains
unknown whether this trend will continue to be positive
through a follow-up stage. This question requires fol-
lowing patients for extended periods of time [15]. In
Norway, it is also particularly important to evaluate
outcomes for patients that were compulsorily admitted
to a hospital. Despite 20 years of practice under a
“Compulsory Treatment Act”, little is known about the
outcomes of these patients. The Norwegian Municipal
Health Care Act, § 10.2 (NMHCA) sanctions involun-
tary interventions for non-psychotic adult patients
with SUDs [16]. The Act covers an option for retention
(up to three months), when the health of the patient is
seriously at risk due to extensive, prolonged substance
use and voluntary efforts have proven insufficient. The
formal decision for compulsory hospitalization is made
by the County Committees, a local board of social welfare,
consisting of legal experts and laypersons. The specialist
health service must take care of these patients in increas-
ing numbers, although both the criteria for compulsory
hospitalization and for what further treatment should be
offered are ill defined in the law-texts [17].
Aims
The aim of this study was to describe QoL in a cohort
of inpatients admitted to voluntary or compulsory
hospitalization for SUD, typically with comorbid psy-
chiatric disorders. Additionally, we aimed to examinechanges in QoL at 6 months post treatment, and iden-
tify predictors of those changes.
Methods
Setting and procedures
This prospective study followed patients with SUD that
were voluntarily and compulsorily hospitalized. The pa-
tients were recruited from three different publicly funded
treatment centers in the southeastern part of Norway. The
centers were located in Kristiansand, Tønsberg, and Oslo.
The treatment wards had multidisciplinary staffs, includ-
ing psychiatrists, psychologists, social workers, occupa-
tional therapists, specialized nurses, and other trained
staff. The centers offered treatment for patients with pri-
mary SUD, often combined with mental disorders (except
psychosis). The patient population was drawn mainly from
urban and suburban areas.
In Norway, patients with SUD that are compulsorily
admitted (CA) and voluntarily admitted (VA) to care are
often treated in a single, gender-mixed ward. In the
acute phase, the main target for the retention of the CA
patients is to provide life-saving treatment; over the long
term, the aim is to motivate them to enter voluntary
treatment [18]. Treatment included assessments of
somatic and mental health. Treatment also included
pharmacotherapy; cognitive milieu therapy; and indi-
vidual motivation enhancement, rather than isolating
the patients.
Recruitment for the study continued consecutively
from January 1, 2009 to May 31, 2011. The criteria for
inclusion were as follows: substance use disorder,
age ≥ 18 years, understanding/speaking the Norwegian
language, and admitted at least 3 weeks prior to study
inclusion allowing them enough time for stabilization.
Before study inclusion, the patients were either detoxi-
fied, which was verified by negative urine tests for alcohol,
opioids, central stimulants (amphetamines, methamphet-
amines, and cocaine), benzodiazepines, and cannabis; or
they spent a minimum of 14 days in detoxification to
establish baseline values not influenced by withdrawal
symptoms. Patients with cognitive disabilities were excluded
when they could not understand the questionnaires. Because
pregnant patients with SUD were treated in special wards,
they were not included in this study. Follow-up interviews
were performed 6 months after discharge from the hospital,
and took place in July 2009 through December 2011.
Participants
A total of 326 patients were identified as potentially rele-
vant for this study, but only 228 were eligible, due to
various reasons, including insufficient mental capacity, a
short stay, or logistical issues. Twenty six refused to par-
ticipate. Thus, 202 patients were enrolled in the study.
Among these, 65 were CA and 137 were VA. The follow-up
Pasareanu et al. Health and Quality of Life Outcomes  (2015) 13:35 Page 3 of 8was conducted at 6 months after discharge from treat-
ment and 123 patients were reached at follow-up (61%).
Significantly more CA patients were included at follow-up
(82% versus 59%). This was due to financial constraints in
the study and the large geographical uptake area. As
patients came from all over the country, it was deemed
necessary to prioritize to reach the CA patients nation-
wide, as compulsory admission was a variable of par-
ticular interest for this study. Thus, the higher loss to
follow-up in the VA group had administrative and logistic
reasons. An attrition analysis showed that there were no
differences between those who dropped out and those
who were reached at follow-up on demographic data, se-
verity scores or length of stay.
Instruments and measures
The Mini International Neuropsychiatric Interview (MINI),
version 5.0, was conducted at baseline to confirm the SUD
diagnosis [19]. In the analysis, SUD diagnosis was dichoto-
mized to alcohol use disorder or drug use disorder. Those
with both alcohol and drug use disorder were coded as
alcohol use disorder. Demographics were recorded.
Substance use variables were assessed based on the
European Addiction Severity Index (EuropASI), a struc-
tured interview designed for both clinical and research
purposes [20].
Psychiatric symptom burdens were measured with the
Symptom Checklist-90-R (SCL-90-R), which contains 90
items, and measures 9 primary symptom dimensions
that provides an overview of a patient’s symptoms and
their intensity. Each of the 90 items is rated on a five-
point Likert-type scale, ranging from “not at all” (0) to
“extremely” (4): higher values indicate greater symptom
severity during the past week. The Global Symptom Index
(GSI) score in SCL-90-R was used to assess the level of
general psychological distress [21]. A cut-off score of GSI>1
was used as a general measure of psychopathology [22].
Quality of life was measured with the QoL-5, a generic
QoL instrument intended to measure satisfaction with
life in general; i.e., it is not disease-specific. Generic in-
struments are preferred in diseases with multidimen-
sional consequences, like SUD [23]. QoL-5 is based on
the integrative theory of the QoL concept [24] and con-
sists of five subjective QoL statements; two questions
about health, physical and mental; two questions about
the quality of the relationship with important others
(partner and friends); and one question about existential
QoL, i.e., the relationship with oneself. Responses were
based on 5-step ordinal scales that varied from 1=very
good to 5=very bad. The raw scores were transposed
into a decimal scale, where 1 = 0.9 (the highest/best
score) and 5 = 0.1 (the lowest/worse score) [25]. Mean
scores for health, relationships, and existential QoL
aspects were calculated, and the total QoL score wascalculated as the mean of these three scores. When
the patient did not have a partner, the relationship sub-
score was calculated based on one question. Normative
data from a general population sample showed a mean
QoL score of 0.69 [26]. The cut-off score for a markedly
low QoL was suggested to be a score below 0.55, and an
extremely low QoL score was < 0.4 [27]. Changes in QoL
were computed by subtracting the QoL determined at ad-
mission from the QoL determined at follow up, hereafter
called the ‘QoL-5 score change’. Thus, a ‘positive score
change’ refers to an improved QoL. A 0.2 or higher score
improvement was considered to be a large, clinically im-
portant improvement; other improvements were consid-
ered moderate (≥0.1 score), small (≥0.05 score), or very
small (<0.05) [23,28].
Treatment variables
Two treatment variables were evaluated in the analyses:
the number of days in treatment and the type of admis-
sion to the hospital: voluntary or compulsory.
Follow up variables
The same variables that were used at baseline were mea-
sured again at the 6-month follow up. Additionally, the
EuropASI was used to measure patient substance use
patterns or abstinence and the number of days spent in
a controlled environment/treatment during the 30 days
preceding the interview.
Missing data
Seven of the 202 participants did not provide QoL-scores
at intake (Table 1). Of the 123 patients reached at follow-
up, one did not proved QoL data. However, due to missing
QoL-scores at intake, only 118 had QoL-scores at both
intake and follow-up, which the longitudinal results
are based on.
Ethics
The study was approved by The Regional Committee for
Research Ethics in Norway (REK 08/206d, 2008/2900,
09/2413) and by the Privacy Issues Unit, Norwegian
Social Science Data Services (NSD no. 18782). Written
informed consent was obtained from all study participants.
Analysis and statistical methods
Continuous variables are reported as means and stand-
ard deviations (SD). Categorical variables are reported as
frequencies. Linear regression was performed to explore
factors that were associated with QoL at baseline. Re-
sults are presented as β-values with 95% confidence
intervals (95% CI). To examine predictors of QoL
score changes, logistic regression was performed. The
QoL-5 score change was dichotomized into groups of
high and low score changes, with a cutoff value of ≥ 0.2
Table 1 Baseline socio-demographic variables, quality of
life, and mental stress scores for patients with substance
use disorder
Variables Number of patients,
N (%) or mean (SD)
Total number of patients, N 202
Mean age, years 30.0 (8.9)
Female gender 68 (34)
Education, years 10.8 (1.9)
Relationship status, single (N=198) 136 (69)
Main diagnosis
Alcohol use disorder 16 (8)
Both alcohol & drug use disorder 18 (9)
Drug use disorder 168 (83)
Severity scores
Injection usea (N=195) 105 (54)
Duration of most problematic
substance use, years
11.1 (7.6)
Global Score Index (SCL-90R – GSI)b 1.2 (0.69)
Treatment variables
Time in treatment, days 57 (26)
Compulsorily admitted 65 (32)
Quality of life (QoL-5 score) (N=195 0.50 (0.16)
aFor the 6 months prior to admission.
bSCL-90-R – GSI: Symptom Check List-90-revised, Global Symptom Index.
Figure 1 Distribution of Quality of Life scores (QoL-5) at
baseline (N=195). The mean QoL-5 was 0.69 in normative data
from a general population sample (green line); a value < 0.55 (yellow
line) is considered a markedly reduced QoL; a value < 0.4 (red line)
is considered a severely reduced QoL.
Table 2 Linear regression analysis shows the effect of
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variate analysis, variables with a p-value < 0.2 were included
in the multivariate analysis [29]. Results are presented as
the odds ratio (OR) with 95% CI. P-values <0.05 were con-
sidered statistically significant. Analyses were performed
with SPSS 18.0 Software (SPSS Inc., Chicago, IL, USA).independent variables on quality of life at baseline in
patients with substance use disorder (SUD), N=195
patientsa
Variable B (95% CI) Pb R2c
Age −0.01 (0.00/0.00) 0.553
Female gender −0.03 (−0.08/0.02) 0.268
Education (years) −0.01 (−0.02/0.05) 0.238
Relationship status, single 0.01 (−0.04/0.06) 0.823Results
The 202 participants had a mean age of 30 years and
34% were females (Table 1). All patients met the ICD-10
criteria for SUD; the majority had a drug use disorder
(83%). For 56% of participants, the mean GSI score
(based on SCL-90) was above the cutoff value for psy-
chiatric pathology.Main SUD diagnosis −0.02 (−0.08/0.04) 0.532
Severity Scores
Injection use 0.11 (−0.38/0.06) 0.671
Years of using most problematic
substance
0.00 (0.00/0.00) 0.942
Global Score Index: SCL-90R - GSI −0.15 (−0.18/-0.12) <0.001 39%
Compulsory hospitalization 0.02 (−0.03/0.07) 0.413
aSeven patients had missing QoL scores at intake.
bP-value obtained from bivariate linear regression. Only one independent
variable had P-value <0.20 in bivariate analyses.
cR2= squared correlation coefficient in order to obtain a measure of explained
variance.QoL at baseline
The QoL at baseline was low for a majority of patients;
59% had a QoL-5 score below 0.55 and 34% had an ex-
tremely low QoL (<0.40, Figure 1). In a linear regression
model, psychiatric symptom distress (SCL90 - GSI) was
the only factor significantly associated with QoL (Table 2).
The SCL90 - GSI explained 39% of the variance in QoL.
Thus, a high psychiatric symptom burden was associated
with a low QoL at baseline. We did not find a significant
association between substance use severity indices andQol, and there were no evidence for a difference in QoL
scores between the CA and VA groups (Table 2).
QoL at follow up 6 months after discharge from hospital
After 6 months, 58% of patients showed a positive change
in QoL score. Improvements in QoL were classified as
large (≥0.20) in 31 patients (26%); moderate (0.10 – 0.19)
in 23 patients (19%); small in 8 patients (7%); and very
small in 7 patients (6%). Forty-nine patients (42%) showed
either no change or deterioration in QoL. The mean QoL-
5 score change showed a significant, though modest, posi-
tive improvement of 0.06 (95% CI = 0.03 – 0.09, t=3.8,
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When analyzed separately the CA group showed a 0.05
mean QoL score improvement (95 % CI = 0.00 – 0.10, p =
0.055), which was of similar magnitude to that observed
in the VA group (0.07, 95% CI = 0.03 – 0.11, p=0.001).
A logistic regression analysis was performed with a large
QoL change (≥0.2) as the dependent variable (Table 3).
The data offered no evidence for a difference between the
CA and VA group in the bivariate analysis, the CA group
had an OR 1.28 (95% CI = 0.56 – 2.94). The multivariate
analysis only retained gender (females) as a predictor, with
an OR of 2.64 (95% CI = 1.12 - 6.22, p=0.026).
Discussion
The majority of patients with SUD that were hospital-
ized had a seriously impaired QoL. A low QoL at base-
line was associated with a high psychiatric symptom
burden. At follow-up, the mean QoL score change
showed a significant, though modest, positive improve-
ment. Patients admitted either voluntarily or compulsor-
ily had QoL improvements of similar magnitude. Female
gender was associated with a clinically relevant improve-
ment in QoL at follow-up.
In this study, we measured QoL with a generic instru-
ment, the QoL-5, in hospitalized patients with SUD. The
results showed a seriously impaired QoL at baseline.
This finding corroborates previous available evidence,
which showed that the QoL was consistently low among
individuals with SUD that were actively seeking treatment,Table 3 Predictors of Quality of Life changea from baseline to
Parameter Bivariate analysis
OR (95% CI)
Age 1.00 (0.96 – 1.05)
Female gender 2.92 (1.12 – 6.71)
Education (years) 1.12 (0.92 –1.37)
Relationship status, single 1.14 (0.43 – 2.80)
Main diagnosis 0.93 (0.33 – 2.60)
Severity scores
Injection use 0.70 (0.31 – 1.53)
Years of using most problematic substance 1.0 (0.96 – 1.01)
Global Score Index: SCL-90R - GSI 1.72 (0.97 – 3.04)
Treatment variables
Days in treatment 1.01 (0.10 – 1.02)
Compulsory treatment 1.28 (0.56 – 2,94)
Follow-up variables
Abstinence at follow-up 1.51 (0.63 – 3.66)
Time in a controlled environment (days)d 1.03 (0.98 1.03)
aThe dependent variable was a dichotomized QoL-5 score change, with a cut-off va
bP-value obtained from bivariate logistic regression.
cP-value obtained from multivariable logistic regression; multivariable analysis inclu
dTime in controlled environment last 30 days before follow-up interview.compared to the general population or individuals with
other chronic health conditions [14]. Patients with SUD
have observed QoL scores as low as or lower than
those of patients with other chronic diseases and sig-
nificantly lower than those of patients awaiting cardiac
surgery [11,30].
We found that the psychiatric symptom burden corre-
lated with the perceived QoL. This was somewhat ex-
pected, because mental function scores on QoL-scales
were previously shown to be remarkably low for patients
with SUD that were entering treatment, and on aver-
age, they were comparable to those found for patients
with clinically-diagnosed depression [30]. Additionally,
most patients with SUD that sought help also exhibited
comorbid symptom disorders and/or personality disor-
ders [31-33]. Somewhat unexpectedly, we found no as-
sociation between the substance use severity indices
and QoL. In a previous, large meta-analysis, the sever-
ity of dependence was the most powerful predictor of a
low QoL [14]. The most unexpected finding was that
the QoL scores were not different between the VA and
CA groups. The NMHCA presupposes that the most
serious cases would be those typically selected for
compulsory treatment. Our findings implied that the
selection of patients for compulsory hospitalization
may not depend entirely on the severity factors; thus,
other variables might be at play in the selection of
these patients (e.g., an intervention by relatives that
















lue of ≥ 0.2 (i.e., a large and clinically relevant QoL change).
ded variables with p-values <0.20 in bivariate analyses.
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though studies were quite limited, showed a tendency
for improvement in the QoL following SUD treatment
[35-37]. Our findings showed no evidence for a differ-
ence in QoL improvements between the CA and VA
groups at the six-month follow-up. This similarity may
be explained by the practice that the treatment for most
patients in the CA group was integrated with that of the
VA group as soon as possible. Other countries, like
Sweden, use special institutions for patients hospitalized
by CA, and they are not integrated with patients hospi-
talized by VA [38]. The quality of treatment is a crucial
factor. Structured, integrated, and long-term treatment
provide superior benefit to a “holding” strategy [38].
Compulsory hospitalization of patients with SUD is a
controversial practice, both ethically and therapeutically.
Many therapists in Norway point out that coercion reduces
the patient’s control, freedom, and self-determination, and
it threatens their autonomy. Therefore, the practice of CA
requires strict regulations and documentation of positive
outcomes. From an utilitarian perspective, it is necessary to
weigh the pros and cons (i.e., the benefits and emotional
costs for the patient) associated with this coercion [39].
Coercion should only be used when the pros outweigh, to
some extent, the cons. This study has provided some pre-
liminary evidence pointing towards beneficial outcomes
also for compulsory treatment, which would be useful in
an ethical debate with an utilitarian perspective.
At follow-up, we found that females showed larger im-
provements in QoL than males. All three wards included
in the present study conducted a gender-mixed treat-
ment program. Currently, in Norway, approximately
70% of patients in SUD treatment are men. Recently,
woman-specific treatment has been advocated to im-
prove outcomes for women [40,41]. Our findings indi-
cated that the mixed-gender treatment provided greater
improvements in QoL for women than for men.
In a review, Gerdner and Berglund point out that
American studies show better outcome for CA than VA
patients owing to better retention in treatment [38].
Swedish studies found no difference between these two
groups. Similarly, we did not find a correlation between
days in treatment and QoL outcome in our study.
Given the low QoL among patients with SUD that
seek treatment, one would intuitively expect an associ-
ation between reduced SUD symptoms and QoL im-
provement, and conversely that QoL would deteriorate
among patients that relapsed [11]. Thus, it was unex-
pected in the present study to find that abstinence at
follow-up was not a predictor for large improvements in
QoL. However, the literature have reported mixed find-
ings; some studies provided evidence that QoL improved
with abstinence [42,43], but others found that there is
not necessarily a link between the two [43,44]. Forexample, there was no correlation between a reduction
in substance use and general life satisfaction among
dually-diagnosed patients three years after assertive
community treatment [44]. Those findings implied that
improved QoL may not rely upon abstinence alone. In
addition to reduced substance use, one should also
focus on a broad range of factors that may underlie pa-
tient evaluation of QoL; most notably, important areas
of recovery, like employment, housing, and means of
social support; e.g., via mutual aid groups [45].
Methodological considerations
This study had some limitations that should be consid-
ered when interpreting the results. There was a high at-
trition rate. However, the attrition analysis showed that
there were no differences between those who dropped
out and those who were included at follow-up with one
exception; a larger proportion of CA patients was reached
at follow-up. The higher drop-out in the VA group was
due to administrative/logistic reasons. Thus, we do not be-
lieve that this has biased or reduced the generalizability of
our findings. The follow-up rate of the CA group was
quite respectable because this group was prioritized and
the sample size was considered large enough for the per-
formed regression analyses [46]. As the sample size and
thus, power was smaller in the sample at follow-up than
at baseline, these findings should be interpreted with cau-
tion. Self-reported information obtained from a QoL ques-
tionnaire poses a challenge in assessing experiences of the
disease in a patient that was hospitalized by CA. Patients
hospitalized by VA may generally be expected to be more
cooperative than those hospitalized by CA. However,
in this study, patients hospitalized by CA were not
approached until they had “settled” down and had
remained for some weeks in the wards; thus, they
were considered competent for consent in participating in
the study. It is not ethical to randomize to voluntary treat-
ment patients that are deemed in need for compulsory
treatment. Conversely; patients that are not deemed in
need for compulsory treatment should not be randomized
to a CA group. Thus, there were no random allocations of
the participants in this study.
The study strengths were that this was, to our know-
ledge, the first study in Norway to assess clinical out-
comes in patients hospitalized by CA. This study also
reported longitudinal data.
Conclusion
We showed that specialized SUD treatment improved QoL
for patients with SUD. Our results also showed that fe-
males benefited more than males from a gender-mixed
treatment paradigm. Our findings pointed to the usefulness
of QoL measurements as evidence of therapeutic benefit in
the recovery process in the SUD field.
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